A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients

Blood

Volumn 124, Issue 19, 2014, Pages 2921-2929

  Stadtmauer, Edward A ^a   Sullivan, Keith M ^b   Marty, Francisco M ^c   Dadwal, Sanjeet S ^d   Papanicolaou, Genovefa A ^e   Shea, Thomas C ^f   Mossad, Sherif B ^g   Andreadis, Charalambos ^h   Young, Jo Anne H ⁱ   Buadi, Francis K ^j   Idrissi, Mohamed El ^k   Heineman, Thomas C ^l   Berkowitz, Elchonon M ^l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j MAYO CLINIC   (United States)

^k GSK   (Belgium)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BIOLOGICAL MARKER; GLYCOPROTEIN E; LENALIDOMIDE; PLACEBO; PLERIXAFOR; SODIUM CHLORIDE; SUBUNIT VACCINE; VARICELLA ZOSTER VACCINE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYALGIA; MYELOABLATIVE CONDITIONING; NAUSEA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; VIRUS IMMUNITY; VOMITING; AUTOTRANSPLANTATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; YOUNG ADULT;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909640008     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-573048     Document Type: Article

References (37)

1. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl 1):S2-S7.
2. Weinberg A, Zhang JH, Oxman MN, et al; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068-1077.
3. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; quiz CE32-CE34.
4. Arvin AM. Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2000;6(3):219-230.
5. Leung TF, Chik KW, Li CK, et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25(2):167-172.
6. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152(6):1172-1181.
7. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989;74(4):1424-1427.
8. Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis. 2011;13(5):480-484.
9. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicellazoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicellazoster virus disease after drug discontinuation. Blood. 2007;110(8):3071-3077.
10. Sempere A, Sanz GF, Senent L, et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant. 1992;10(6):495-498.
11. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with lowdose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25(6):657-664.
12. Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
13. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60(44):1528.
14. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
15. Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8(5):259-270.
16. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26-34.
17. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176(3):578-585.
18. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel). 2005;121:153-163.
19. Arvin AM. Immune responses to varicella-zoster virus. Infect Dis Clin North Am. 1996;10(3):529-570.
20. Grose C. Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol. 1990;44:59-80.
21. Ali MA, Li Q, Fischer ER, Cohen JI. The insulin degrading enzyme binding domain of varicellazoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection. Virology. 2009;386(2):270-279.
22. Berarducci B, Rajamani J, Zerboni L, Che X, Sommer M, Arvin AM. Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci USA. 2010;107(1):282-287.
23. Arvin AM, Kinney-Thomas E, Shriver K, et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol. 1986;137(4):1346-1351.
24. Brunell PA, Novelli VM, Keller PM, Ellis RW. Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response. J Infect Dis. 1987;156(3):430-435.
25. Harper DR, Kangro HO, Heath RB. Antibody responses in recipients of varicella vaccine assayed by immunoblotting. J Med Virol. 1990;30(1):61-67.
26. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD41 T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152(3):522-531.
27. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206(8):1280-1290.
28. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471-486.
29. Wang SK, Tsiatis AA. Approximately optimal oneparameter boundaries for group sequential trials. Biometrics. 1987;43(1):193-199.
30. Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicellazoster virus subunit candidate vaccine against herpes zoster in adults $50 years of age. J Infect Dis. 2013;208(12):1953-1961.
31. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848-857.
32. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603-3613.
33. Kumar S. Stem cell transplantation for multiple myeloma. Curr Opin Oncol. 2009;21(2):162-170.
34. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009;23(3):449-456.
35. Offidani M, Corvatta L, Olivieri A, et al. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis. 2001;32(10):1414-1422.
36. Ljungman P, Cordonnier C, Einsele H, et al; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521-526.
37. ®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87(1):123-125.